Disc Medicine prices upsized $250M offering; net proceeds ~$210.9M to fund bitopertin and extend cash runway into 2029

Disc Medicine, Inc.

Net proceeds to Disc Medicine expected ~$210.9M; funds will support bitopertin commercialization for EPP/XLP, R&D, and general corporate purposes.
Selling stockholder AI DMI LLC sold 297,619 shares at $84.00; underwriters exercised option to purchase additional 446,428 shares from AI DMI.
Company expects cash, equivalents, and marketable securities plus offering net proceeds to fund operations into 2029, excluding potential bitopertin revenue.
Pre-funded warrants have $0.0001 exercise price, immediate exercisability, and 24.99% ownership limit; not listed on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.